INDICATIONS
Neofloxin is indicated for the treatment of a wide variety of infecfions caused by susceptible
gram-positive and gram-negative organisms including mixed infections caused by two or more
organisms.
The extensive tissue penetration of Neofloxin combined with its enhanced antibacterial activity
(including anti-pseudomonal activity) enables Neofloxin to be used alone pending sensitivity
results or in combination with an aminoglycoside or with beta-lactam antibiotics or with an
antibiotic active against anaerobes (metronidazole) where the presence of anaerobes is
suspected.
Neofloxin is indicated for the treatment of the following infections caused by sensitive bacteria :
1 . Respiratory Tract Infections – pneumonia, bronchopneumonia, infected pleurisy, empyema,
lung abscess, infected bronchiectasis, acute exacerbation of chronic bronchitis
and lung infections in patients with cystic fibrosis.
2. Ear, Nose and Throat Infections – otitis media, sinusitis, mastoiditis.
3. Gastrointestinal Tract Infections – enteric fever, infective diarrhoea.
4. Intra-abdominal Infections – peritonitis, intra-abdominal abscess, cholangitis, cholecystitis,
empyema of gall bladder.
5. Skin and Soft Tissue Infections – Infected ulcers, wound infections, abscesses, cellulitis,
otitis externa, infected burns.
6. Bone and Joint Infections – acute and chronic osteomyelitis, septic arthritis.
7 Urinary Tract Infections – acute and chronic pyelonephritis, prostatitis, cystitis, epididymitis
and chronic, complicated or recurrent UTI.
8. Gonorrhoea including urethral, rectal and pharyngeal gonococcal infections even those
caused by resistant gonococci.
9. Gynaecological Infections – Salpingitis, endometritis, pelvic inflammatory disease.
I 0. Eye infections – bacterial conjunctivitis.
11. Severe Systemic Infections – Septicemia, bacteremia and infections in immunocompromised
patients.
Neofloxin is also indicated for prophylaxis against infection in elective upper-gastrointestinal
surgery and endoscopic procedures where there is an increased risk of infection.
DOSAGE AND ADMINISTRATlON
The dosage of Neofloxin is determined by the severity and type of infection, the sensitivity of
the causative organism(s) and the age, weight, and renal function of the patient. The usual
intravenous dose is 100 to 400mg twice daily.
Indications Dosage Infusion Rate Duration
Upper and 100mg (50ml) every 12 Should be The duration of treatment
Lower UTI hourly administered depends upon the severity
by slow of infection, clinical
intravenous response and
infusion over bacteriological findings.The
Lower RTI 200mg (100ml) every 12 periods of usual duration of therapy for
hourly 30-60 minutes acute infections is 5 to 7
days. Generally, therapy
Other 200mg (100ml) every 12 should be continued for at
Infections hourly least 3 days after the signs
and symptoms of the
Gonorrhoea 100mg (50ml) as a single infection have disappeared.
dose
Children : Ciprofloxacin is usually not recommended for use in children. However, if the benefits
of Ciprofloxacin therapy are considered to outweigh the potential risk, the dosage should be 5-
10mg/kg/day in 2 divided doses, depending on the severity of infection.
Neofloxin infusion is compatible with sodium chloride 0.9% solution, Ringer’s solution, glucose
5% and 10% solutions, glucose/saline and fructose 10% solution. Unless compatibility is
proven, the infusion should always be administered separately.
CONTRAINDICATIONS
Ciprofloxacin is contraindicated in individuals with a history of hypersensitivity to this drug. It is
also contraindicated in children and growing adolescents except where the benefits of treatment
exceed the risks.
PRECAUTIONS
Ciprofloxacin should be used with caution in epileptics and patients with a history of CNS
disorders. Ciprofloxacin could result in an impairment of the patients ability to drive or operate
machinery, particularly in conjunction with alcohol. Patients receiving this drug should be well
hydrated and excessive alkalinity of urine should be avoided.
USE IN PREGNANCY AND LACTATION
Reproduction study with Ciprofloxacin did not reveal any evidence of teratogenicity, impairment
of fertility or impairment of peri/post-natal development. Ciprofloxacin has been shown to cause
arthropathy in immature animals. It is secreted in breast milk. So Ciprofloxacin should not be
used in pregnant and nursing women.
Reviews
There are no reviews yet.